SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Discloses 9.9% Stake in Tenax Therapeutics
Beneficial Ownership Report
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.9% in Tenax Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y Koh (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
- The Reporting Persons collectively beneficially own 417,541 shares of Tenax Therapeutics, Inc. Common Stock.
- This aggregate amount represents 9.9% of the Issuer's outstanding Common Stock, rounded down from 9.99% due to EDGAR filing system limitations.
- The ownership includes direct shares, pre-funded warrants, and common warrants, but their exercise is limited by a "Beneficial Ownership Blocker" provision.
- The Beneficial Ownership Blocker prevents the Reporting Persons from exercising warrants if it would result in their collective ownership exceeding 9.99% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 3,970,385 shares of Common Stock outstanding as of March 21, 2025, plus 209,208 shares issuable upon the exercise of warrants, totaling 4,179,593 shares for the calculation base.
Sentiment
Score: 5
Explanation: This document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake and its limitations due to the beneficial ownership blocker.
Key Dates
| Date | Description |
|---|---|
| 03/21/2025 | Date of Common Stock outstanding reported in Issuer's Annual Report on Form 10-K. |
| 03/25/2025 | Date Issuer's Annual Report on Form 10-K was filed with the SEC. |
| 03/31/2025 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 05/15/2025 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Tenax Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G, beneficial ownership, common stock, warrants, institutional ownership, SEC filing, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.